← Calendar
Readoutin 135d
Sanofi — Isatuximab SAR650984
Phase 3 primary completion: A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant.
- Date
- Apr 2027
- Type
- Readout
- Indication
- Plasma Cell Myeloma
Source ↗Add to calendar
Get told when this date moves
The weekly brief is free. Pro adds reminders 7 days and 1 day before.
More from Sanofi
May2027
Readoutin 165d
Sanofi — FrexalimabPhase 3 primary completion: Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis.
Nov2026
ReadoutIn window
Sanofi — Yellow fever vaccine (live)Phase 3 primary completion: A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population.